188 related articles for article (PubMed ID: 26650078)
21. Combination vaccine against invasive meningococcal B and pneumococcal infections: potential epidemiological and economic impact in the Netherlands.
Bos JM; Rümke HC; Welte R; Spanjaard L; van Alphen L; Postma MJ
Pharmacoeconomics; 2006; 24(2):141-53. PubMed ID: 16460135
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness analysis of pneumococcal conjugate vaccine introduction in Paraguay.
Kieninger MP; Caballero EG; Sosa AA; Amarilla CT; Jáuregui B; Janusz CB; Clark AD; Castellanos RM
Vaccine; 2015 May; 33 Suppl 1():A143-53. PubMed ID: 25919155
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness of 13-valent pneumococcal conjugate vaccination in Mongolia.
Sundaram N; Chen C; Yoong J; Luvsan ME; Fox K; Sarankhuu A; La Vincente S; Jit M
Vaccine; 2017 Feb; 35(7):1055-1063. PubMed ID: 28109706
[TBL] [Abstract][Full Text] [Related]
24. A pharmacoeconomic evaluation of seven-valent pneumococcal conjugate vaccine in Spain.
Asensi F; De Jose M; Lorente M; Moraga F; Ciuryla V; Arikian S; Casciano R; Vento M
Value Health; 2004; 7(1):36-51. PubMed ID: 14720129
[TBL] [Abstract][Full Text] [Related]
25. Estimating the cost-effectiveness of an infant 13-valent pneumococcal conjugate vaccine national immunization program in China.
Shen K; Wasserman M; Liu D; Yang YH; Yang J; Guzauskas GF; Wang BCM; Hilton B; Farkouh R
PLoS One; 2018; 13(7):e0201245. PubMed ID: 30044865
[TBL] [Abstract][Full Text] [Related]
26. Epidemiologic impact and cost-effectiveness of universal infant vaccination with a 7-valent conjugated pneumococcal vaccine in the Netherlands.
Bos JM; Rümke H; Welte R; Postma MJ
Clin Ther; 2003 Oct; 25(10):2614-30. PubMed ID: 14667962
[TBL] [Abstract][Full Text] [Related]
27. The pharmacoeconomics of pneumococcal conjugate vaccines in Latin America.
Giglio N; Micone P; Gentile A
Vaccine; 2011 Sep; 29 Suppl 3():C35-42. PubMed ID: 21896351
[TBL] [Abstract][Full Text] [Related]
28. Who benefits most from extending financial protection for cataract surgery in Vietnam? An extended cost-effectiveness analysis of small incision surgery.
Essue BM; Jan S; Phuc HT; Dodson S; Armstrong K; Laba TL
Health Policy Plan; 2020 May; 35(4):399-407. PubMed ID: 32031615
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines.
Tyo KR; Rosen MM; Zeng W; Yap M; Pwee KH; Ang LW; Shepard DS
Vaccine; 2011 Sep; 29(38):6686-94. PubMed ID: 21745516
[TBL] [Abstract][Full Text] [Related]
30. Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children.
Lieu TA; Ray GT; Black SB; Butler JC; Klein JO; Breiman RF; Miller MA; Shinefield HR
JAMA; 2000 Mar; 283(11):1460-8. PubMed ID: 10732936
[TBL] [Abstract][Full Text] [Related]
31. Impact of routine PCV7 (Prevenar) vaccination of infants on the clinical and economic burden of pneumococcal disease in Malaysia.
Aljunid S; Abuduxike G; Ahmed Z; Sulong S; Nur AM; Goh A
BMC Infect Dis; 2011 Sep; 11():248. PubMed ID: 21936928
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales.
Melegaro A; Edmunds WJ
Vaccine; 2004 Oct; 22(31-32):4203-14. PubMed ID: 15474710
[TBL] [Abstract][Full Text] [Related]
33. Addressing child health inequity through case management of under-five malaria in Nigeria: an extended cost-effectiveness analysis.
Dasgupta RR; Mao W; Ogbuoji O
Malar J; 2022 Mar; 21(1):81. PubMed ID: 35264153
[TBL] [Abstract][Full Text] [Related]
34. Vaccination of risk groups in England using the 13 valent pneumococcal conjugate vaccine: economic analysis.
Rozenbaum MH; van Hoek AJ; Fleming D; Trotter CL; Miller E; Edmunds WJ
BMJ; 2012 Oct; 345():e6879. PubMed ID: 23103369
[TBL] [Abstract][Full Text] [Related]
35. Sustaining pneumococcal vaccination after transitioning from Gavi support: a modelling and cost-effectiveness study in Kenya.
Ojal J; Griffiths U; Hammitt LL; Adetifa I; Akech D; Tabu C; Scott JAG; Flasche S
Lancet Glob Health; 2019 May; 7(5):e644-e654. PubMed ID: 31000132
[TBL] [Abstract][Full Text] [Related]
36. Potential impact of introducing the pneumococcal conjugate vaccine into national immunisation programmes: an economic-epidemiological analysis using data from India.
Megiddo I; Klein E; Laxminarayan R
BMJ Glob Health; 2018; 3(3):e000636. PubMed ID: 29765775
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness analysis of infant pneumococcal vaccination with PHiD-CV in Korea.
Zhang XH; Leeuwenkamp O; Oh KB; Lee YE; Kim CM
Hum Vaccin Immunother; 2018 Jan; 14(1):85-94. PubMed ID: 29115905
[TBL] [Abstract][Full Text] [Related]
38. Effects of public financing of essential maternal and child health interventions across wealth quintiles in Nigeria: an extended cost-effectiveness analysis.
Mao W; Watkins D; Sabin ML; Huang K; Langlois E; Ogundeji Y; Fogstad H; Schäferhoff M; Yamey G; Ogbuoji O
Lancet Glob Health; 2023 Apr; 11(4):e597-e605. PubMed ID: 36925179
[TBL] [Abstract][Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]